## Louis Potters

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9537519/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Implementation of External Beam Five-Fraction Adjuvant Breast Irradiation in a US Center. Cancers, 2022, 14, 1556.	3.7	5
2	Non-adherence to multi-modality cancer treatment guidelines in the United States. Advances in Radiation Oncology, 2022, 7, 100938.	1.2	3
3	Biological effective dose in analysis of rectal dose in prostate cancer patients who underwent a combination therapy of VMAT and LDR with hydrogel spacer insertion. Journal of Applied Clinical Medical Physics, 2022, , e13584.	1.9	3
4	Posttraumatic Growth in Radiation Medicine During the COVID-19 Outbreak. Advances in Radiation Oncology, 2022, 7, 100975.	1.2	4
5	Assessing initial plan check efficacy using TG 275 failure modes and incident reporting. Journal of Applied Clinical Medical Physics, 2022, , e13640.	1.9	2
6	Biochemical Control and Toxicity Outcomes of Stereotactic Body Radiation Therapy Versus Low-Dose-Rate Brachytherapy in the Treatment of Low- and Intermediate-Risk Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2021, 109, 1232-1242.	0.8	9
7	SCAROP Letter to Academic Chairs: Racial Justice and Health Equity. International Journal of Radiation Oncology Biology Physics, 2021, 109, 36-37.	0.8	0
8	Implementation of Telehealth in Radiation Oncology: Rapid Integration During COVID-19 and Its Future Role in Our Practice. Advances in Radiation Oncology, 2021, 6, 100575.	1.2	20
9	Executive Summary of the American Radium Society Appropriate Use Criteria for Radiation Treatment of Node-Negative Muscle Invasive Bladder Cancer. International Journal of Radiation Oncology Biology Physics, 2021, 109, 953-963.	0.8	6
10	Computed tomography-based flap brachytherapy for non-melanoma skin cancers of the face. Journal of Contemporary Brachytherapy, 2021, 13, 51-58.	0.9	6
11	When in a Hole, Stop Digging. International Journal of Radiation Oncology Biology Physics, 2021, 110, 272-273.	0.8	2
12	Low dose rate brachytherapy for primary treatment of localized prostate cancer: A systemic review and executive summary of an evidence-based consensus statement. Brachytherapy, 2021, 20, 1114-1129.	0.5	26
13	Impact of the COVID-19 Pandemic Surge on Radiation Treatment: Report From a Multicenter New York Area Institution. JCO Oncology Practice, 2021, 17, e1270-e1277.	2.9	13
14	Automated health chats for symptom management of head and neck cancer patients undergoing radiation therapy. Oral Oncology, 2021, 122, 105551.	1.5	7
15	The Top Concerns of Radiation Oncology Trainees in 2019: A Response from SCAROP. International Journal of Radiation Oncology Biology Physics, 2020, 106, 26-28.	0.8	2
16	Prospective Peer Review in Radiation Therapy Treatment Planning: Long-Term Results From a Longitudinal Study. Practical Radiation Oncology, 2020, 10, e199-e206.	2.1	18
17	Restructuring Our Approach to Peer Review: A Critical Need to Improve the Quality and Safety of Radiation Therapy. Practical Radiation Oncology, 2020, 10, 321-323.	2.1	5
18	The Resilience of Radiation Oncology in the COVID Era and Beyond. International Journal of Radiation Oncology Biology Physics, 2020, 108, 364-369.	0.8	3

#	Article	IF	CITATIONS
19	Guidelines to Reduce Hospitalization Rates for Patients Receiving Curative-Intent Radiation Therapy During the COVID-19 Pandemic: Report From a Multicenter New York Area Institution. Advances in Radiation Oncology, 2020, 5, 621-627.	1.2	19
20	Development and execution of a pandemic preparedness plan: Therapeutic medical physics and radiation dosimetry during the COVIDâ€19 crisis. Journal of Applied Clinical Medical Physics, 2020, 21, 259-265.	1.9	6
21	Disease Site-Specific Guidelines for Curative Radiation Treatment During â€~Limited Surgery' and â€~Hospital Avoidance': A Radiation Oncology Perspective From the Epicenter of COVID-19 Pandemic. Cureus, 2020, 12, e8190.	0.5	7
22	Impact of Multi-Institutional Prospective Peer Review on Target and Organ-at-Risk Delineation in Radiation Therapy. Practical Radiation Oncology, 2019, 9, e228-e235.	2.1	13
23	Outcomes of a Dose-Escalated Stereotactic Body Radiation Phase 1 Trial for Patients With Low- and Intermediate-Risk Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2019, 104, 334-342.	0.8	10
24	Commentary in reply to: Gross etÂal, Radiation Oncologists' Role in End-of-Life Care: A Perspective From Medical Oncologists. Practical Radiation Oncology, 2019, 9, 371-372.	2.1	0
25	A Model-based method for assessment of salivary gland and planning target volume dosimetry in volumetric-modulated arc therapy planning on head-and-neck cancer. Journal of Medical Physics, 2019, 44, 201.	0.3	3
26	Common error pathways seen in the RO-ILS data that demonstrate opportunities for improving treatment safety. Practical Radiation Oncology, 2018, 8, 123-132.	2.1	45
27	Implementation and utilization of hypofractionation for breast cancer. Advances in Radiation Oncology, 2018, 3, 265-270.	1.2	13
28	Defining the value of magnetic resonance imaging in prostate brachytherapy using time-driven activity-based costing. Brachytherapy, 2017, 16, 665-671.	0.5	13
29	Accuracy evaluation of a sixâ€degreeâ€ofâ€freedom couch using cone beam <scp>CT</scp> and IsoCal phantom with an inâ€house algorithm. Medical Physics, 2017, 44, 3888-3898.	3.0	9
30	Improving efficiency and safety in external beam radiation therapy treatment delivery using a Kaizen approach. Practical Radiation Oncology, 2017, 7, e499-e506.	2.1	9
31	In vivo dosimetry with optically stimulated luminescent dosimeters for conformal and intensity-modulated radiation therapy: A 2-year multicenter cohort study. Practical Radiation Oncology, 2017, 7, e135-e144.	2.1	12
32	Preventing Discontinuation of Radiation Therapy: Predictive Factors to Improve Patient Selection for Palliative Treatment. Journal of Oncology Practice, 2017, 13, e782-e791.	2.5	12
33	Deformable image registration and interobserver variation in contour propagation for radiation therapy planning. Journal of Applied Clinical Medical Physics, 2016, 17, 347-357.	1.9	17
34	Defining the value framework for prostate brachytherapy using patient-centered outcome metrics and time-driven activity-based costing. Brachytherapy, 2016, 15, 274-282.	0.5	37
35	A Systems Approach Using Big Data to Improve Safety and Quality in Radiation Oncology. International Journal of Radiation Oncology Biology Physics, 2016, 95, 885-889.	0.8	19
36	Comparison of True Cost Between Modalities in a Changing American Healthcare System. , 2016, , 105-118		0

#	Article	IF	CITATIONS
37	The dangers of incorporating reimbursement data into clinical decision making. Practical Radiation Oncology, 2015, 5, 274-276.	2.1	2
38	Prospective contouring rounds: A novel, high-impact tool for optimizing quality assurance. Practical Radiation Oncology, 2015, 5, e431-e436.	2.1	41
39	A systematic review of randomised controlled trials of radiotherapy for localised prostate cancer. European Journal of Cancer, 2015, 51, 2345-2367.	2.8	81
40	Research on Quality and Safety: What Are We Missing?. International Journal of Radiation Oncology Biology Physics, 2015, 91, 17-19.	0.8	4
41	Physician Attitudes and Practices Related to Voluntary Error and Near-Miss Reporting. Journal of Oncology Practice, 2014, 10, e350-e357.	2.5	39
42	Choosing Wisely: The American Society for Radiation Oncology's Top 5 list. Practical Radiation Oncology, 2014, 4, 349-355.	2.1	102
43	Establishing High-Quality Prostate Brachytherapy Using a Phantom Simulator Training Program. International Journal of Radiation Oncology Biology Physics, 2014, 90, 579-586.	0.8	43
44	The safety hazard. Practical Radiation Oncology, 2014, 4, 215-216.	2.1	1
45	American Society for Radiation Oncology's Performance Assessment for the Advancement of Radiation Oncology Treatment: A practical approach for informing practice improvement. Practical Radiation Oncology, 2013, 3, e37-e43.	2.1	2
46	In Reply to Baer. International Journal of Radiation Oncology Biology Physics, 2013, 85, 897.	0.8	0
47	Incident Learning and Failure-Mode-and-Effects-Analysis Guided Safety Initiatives in Radiation Medicine. Frontiers in Oncology, 2013, 3, 305.	2.8	23
48	Development, Implementation, and Compliance of Treatment Pathways in Radiation Medicine. Frontiers in Oncology, 2013, 3, 105.	2.8	18
49	Practice-Based Evidence to Evidence-Based Practice: Building the National Radiation Oncology Registry. Journal of Oncology Practice, 2013, 9, e90-e95.	2.5	29
50	American College of Radiology (ACR) and American Society for Radiation Oncology (ASTRO) Practice Guideline for the Performance of Stereotactic Radiosurgery (SRS). American Journal of Clinical Oncology: Cancer Clinical Trials, 2013, 36, 310-315.	1.3	91
51	Is a Half-Truth a Whole Lie?. Journal of Oncology Practice, 2013, 9, 63-64.	2.5	0
52	Our Pledge to Achieve Safety. International Journal of Radiation Oncology Biology Physics, 2012, 82, 1310-1311.	0.8	7
53	The Paradox of Multidisciplinary Care. International Journal of Radiation Oncology Biology Physics, 2012, 84, 20-22.	0.8	6
54	American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy. Brachytherapy, 2012, 11, 6-19.	0.5	399

#	Article	IF	CITATIONS
55	Implementation of a "No Fly―safety culture in a multicenter radiation medicine department. Practical Radiation Oncology, 2012, 2, 18-26.	2.1	22
56	Quality and safety considerations in stereotactic radiosurgery and stereotactic body radiation therapy: Executive summary. Practical Radiation Oncology, 2012, 2, 2-9.	2.1	164
57	Six sigma tools for a patient safety-oriented, quality-checklist driven radiation medicine department. Practical Radiation Oncology, 2012, 2, 86-96.	2.1	42
58	VALIDATION AND COMPARISON OF THE TWO KATTAN NOMOGRAMS IN PATIENTS WITH PROSTATE CANCER TREATED WITH <sup>125</sup> IODINE BRACHYTHERAPY. BJU International, 2012, 109, 1665-1665.	2.5	0
59	Apples to apples. Brachytherapy, 2011, 10, 15.	0.5	0
60	American Society for Radiation Oncology (ASTRO) and American College of Radiology (ACR) Practice Guideline for the Transperineal Permanent Brachytherapy of Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2011, 79, 335-341.	0.8	68
61	Postoperative Nomogram Predicting the 9-Year Probability of Prostate Cancer Recurrence After Permanent Prostate Brachytherapy Using Radiation Dose as a Prognostic Variable. International Journal of Radiation Oncology Biology Physics, 2010, 76, 1061-1065.	0.8	59
62	American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) Practice Guidelines for Image-Guided Radiation Therapy (IGRT). International Journal of Radiation Oncology Biology Physics, 2010, 76, 319-325.	0.8	90
63	American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) Practice Guideline for the Performance of Stereotactic Body Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2010, 76, 326-332.	0.8	473
64	The second decade of prostate brachytherapy: Evidence and cost based outcomes. Urologic Oncology: Seminars and Original Investigations, 2010, 28, 86-90.	1.6	9
65	Synuclein Î <sup>3</sup> Stimulates Membrane-Initiated Estrogen Signaling by Chaperoning Estrogen Receptor (ER)-α36, a Variant of ER-α. American Journal of Pathology, 2010, 177, 964-973.	3.8	30
66	Radiation therapy approaches to the treatment of high-risk prostate cancer. Current Prostate Reports, 2009, 7, 95-101.	0.1	0
67	Radiation therapy approaches to the treatment of high-risk prostate cancer. Current Urology Reports, 2009, 10, 187-193.	2.2	0
68	Multicenter Analysis of Effect of High Biologic Effective Dose on Biochemical Failure and Survival Outcomes in Patients With Gleason Score 7–10 Prostate Cancer Treated With Permanent Prostate Brachytherapy. International Journal of Radiation Oncology Biology Physics, 2009, 73, 341-346.	0.8	126
69	Long-Term Outcomes in Younger Men Following Permanent Prostate Brachytherapy. Journal of Urology, 2009, 181, 1665-1671.	0.4	44
70	Vitexins, Nature-Derived Lignan Compounds, Induce Apoptosis and Suppress Tumor Growth. Clinical Cancer Research, 2009, 15, 5161-5169.	7.0	118
71	LONG-TERM OUTCOMES IN YOUNGER MEN FOLLOWING PERMANENT PROSTATE BRACHYTHERAPY. Journal of Urology, 2009, 181, 210-210.	0.4	1
72	Assessment of External Beam Radiation Technology for Dose Escalation and Normal Tissue Protection in the Treatment of Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2008, 70, 671-677.	0.8	19

#	Article	IF	CITATIONS
73	In Reply to Drs. Oton and Oton. International Journal of Radiation Oncology Biology Physics, 2008, 71, 962-963.	0.8	0
74	12-Year Outcomes Following Permanent Prostate Brachytherapy in Patients with Clinically Localized Prostate Cancer. Journal of Urology, 2008, 179, S20-4.	0.4	146
75	Multi-institutional analysis of long-term outcome for stages T1–T2 prostate cancer treated with permanent seed implantation. International Journal of Radiation Oncology Biology Physics, 2007, 67, 327-333.	0.8	440
76	The Art of Radiation Oncology?. International Journal of Radiation Oncology Biology Physics, 2007, 68, 966-967.	0.8	1
77	Customized Dose Prescription for Permanent Prostate Brachytherapy: Insights From a Multicenter Analysis of Dosimetry Outcomes. International Journal of Radiation Oncology Biology Physics, 2007, 69, 1472-1477.	0.8	92
78	Dynamic dose-feedback prostate brachytherapy in patients with large prostates and/or planned transurethral surgery before implantation. BJU International, 2007, 99, 1066-1071.	2.5	6
79	Interstitial implant alone or in combination with external beam radiation therapy for intermediate-risk prostate cancer: A survey of practice patterns in the United States. Brachytherapy, 2007, 6, 2-8.	0.5	47
80	Practice guideline for the performance of therapy with unsealed radiopharmaceutical sources. International Journal of Radiation Oncology Biology Physics, 2006, 64, 1299-1307.	0.8	9
81	Permanent prostate brachytherapy: Dosimetric results and analysis of a learning curve with a dynamic dose-feedback technique. International Journal of Radiation Oncology Biology Physics, 2006, 65, 694-698.	0.8	22
82	Is there a role for postimplant dosimetry after real-time dynamic permanent prostate brachytherapy?. International Journal of Radiation Oncology Biology Physics, 2006, 65, 1014-1019.	0.8	26
83	A multicenter study demonstrating discordant results from electronic prostate-specific antigen biochemical failure calculation systems. International Journal of Radiation Oncology Biology Physics, 2006, 65, 1494-1500.	0.8	6
84	Comparison of biochemical failure definitions for permanent prostate brachytherapy. International Journal of Radiation Oncology Biology Physics, 2006, 65, 1487-1493.	0.8	110
85	Critical organ dosimetry in permanent seed prostate brachytherapy: Defining the organs at risk. Brachytherapy, 2005, 4, 186-194.	0.5	80
86	Stereotactic Body Radiation Therapy. Journal of the American College of Radiology, 2005, 2, 676-680.	1.8	13
87	12-YEAR OUTCOMES FOLLOWING PERMANENT PROSTATE BRACHYTHERAPY IN PATIENTS WITH CLINICALLY LOCALIZED PROSTATE CANCER. Journal of Urology, 2005, 173, 1562-1566.	0.4	275
88	Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy ≥72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1–T2 prostate cancer. International Journal of Radiation Oncology Biology Physics, 2004, 58, 25-33.	0.8	440
89	American Society for Therapeutic Radiology and Oncology* and American College of Radiology Practice Guideline for the Performance of Stereotactic Body Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2004, 60, 1026-1032.	0.8	191
90	Monotherapy for stage T1–T2 prostate cancer: radical prostatectomy, external beam radiotherapy, or permanent seed implantation. Radiotherapy and Oncology, 2004, 71, 29-33.	0.6	172

#	Article	lF	CITATIONS
91	A chronological database to support outcomes research in prostate cancer. International Journal of Radiation Oncology Biology Physics, 2003, 56, 1252-1258.	0.8	9
92	Toward a dynamic real-time intraoperative permanent prostate brachytherapy methodology. Brachytherapy, 2003, 2, 172-180.	0.5	40
93	The prognostic significance of Gleason grade in patients treated with permanent prostate brachytherapy. International Journal of Radiation Oncology Biology Physics, 2003, 56, 749-754.	0.8	28
94	How one defines intensity-modulated radiation therapy. International Journal of Radiation Oncology Biology Physics, 2003, 56, 609-610.	0.8	14
95	The effect of isotope selection on the prostate-specific antigen response in patients treated with permanent prostate brachytherapy. Brachytherapy, 2003, 2, 26-31.	0.5	6
96	Importance of implant dosimetry for patients undergoing prostate brachytherapy. Urology, 2003, 62, 1073-1077.	1.0	63
97	Impact of Intraoperative Edema During Transperineal Permanent Prostate Brachytherapy on Computer-Optimized and Preimplant Planning Techniques. American Journal of Clinical Oncology: Cancer Clinical Trials, 2003, 26, e130-e135.	1.3	41
98	A comprehensive and novel predictive modeling technique using detailed pathology factors in men with localized prostate carcinoma. Cancer, 2002, 95, 1451-1456.	4.1	17
99	External radiotherapy and permanent prostate brachytherapy in patients with localized prostate cancer•. Brachytherapy, 2002, 1, 36-41.	0.5	17
100	Prognostic significance of race on biochemical control in patients with localized prostate cancer treated with permanent brachytherapy: multivariate and matched-pair analyses. International Journal of Radiation Oncology Biology Physics, 2002, 53, 282-289.	0.8	16
101	Nomograms for clinically localized prostate cancer. Part II: Radiation therapy. Urologic Oncology, 2002, 20, 131-139.	1.5	2
102	Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer. Urology, 2001, 58, 393-399.	1.0	199
103	A comprehensive review of CT-based dosimetry parameters and biochemical control in patients treated with permanent prostate brachytherapy. International Journal of Radiation Oncology Biology Physics, 2001, 50, 605-614.	0.8	248
104	Potency after permanent prostate brachytherapy for localized prostate cancer. International Journal of Radiation Oncology Biology Physics, 2001, 50, 1235-1242.	0.8	182
105	A theoretical derivation of the nomograms for permanent prostate brachytherapy. Medical Physics, 2001, 28, 683-687.	3.0	11
106	Iodine-125 vs. Palladium-103: Long-term complications. , 2000, 90, 110-110.		0
107	Rectal complications associated with transperineal interstitial brachytherapy for prostate cancer. International Journal of Radiation Oncology Biology Physics, 2000, 48, 119-124.	0.8	167
108	The definition of biochemical failure in patients treated with definitive radiotherapy. International Journal of Radiation Oncology Biology Physics, 2000, 48, 1469-1474.	0.8	69

#	Article	IF	CITATIONS
109	Examining the Role of Neoadjuvant Androgen Deprivation in Patients Undergoing Prostate Brachytherapy. Journal of Clinical Oncology, 2000, 18, 1187-1192.	1.6	125
110	The role of external beam irradiation in patients undergoing prostate brachytherapy. Urologic Oncology: Seminars and Original Investigations, 2000, 5, 112-117.	1.6	12
111	Urinary morbidity following ultrasound-guided transperineal prostate seed implantation. International Journal of Radiation Oncology Biology Physics, 1999, 45, 59-67.	0.8	255
112	Isotope selection for patients undergoing prostate brachytherapy. International Journal of Radiation Oncology Biology Physics, 1999, 45, 391-395.	0.8	56
113	Pelvic control following external beam radiation for surgical stage I endometrial adenocarcinoma. International Journal of Radiation Oncology Biology Physics, 1995, 33, 851-854.	0.8	32
114	Comprehensive management including interstitial brachytherapy for locally advanced or recurrent gynecologic malignancies. Gynecologic Oncology, 1992, 46, 322-325.	1.4	14
115	Locally advanced paranasal sinus and nasopharynx tumors treated with hyperfractionated radiation and concomitant infusion cisplatin. Cancer, 1991, 67, 2748-2752.	4.1	37
116	Diminished Survival of Young Blacks With Adenocarcinoma of the Prostate. American Journal of Clinical Oncology: Cancer Clinical Trials, 1990, 13, 465-469.	1.3	63